DrugPatentWatch Database Preview
Patent: 9,434,785
» See Plans and Pricing
Summary for Patent: 9,434,785
| Title: | Anti-human OX40L antibodies and methods of treating graft versus host disease with the same |
| Abstract: | The present invention relates to anti-human OX40L antibodies, new medical uses and methods. |
| Inventor(s): | Bland-Ward; Philip (Cambridge, GB), Campbell; Jamie (Cambridge, GB), Holmes; Steve (Cambridge, GB), Kirby; Ian (Cambridge, GB), Kosmac; Miha (Cambridge, GB), Kean; Leslie Susan (Seattle, WA), Tkachev; Victor (Seattle, WA) |
| Assignee: | Kymab Limited (Cambridge, GB) |
| Application Number: | 14/935,937 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,434,785
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 002 | 2017-06-22 | Start Trial | Kymab Limited (Cambridge, GB) | 2035-09-09 | RX | Orphan | search |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 001 | 2017-06-22 | Start Trial | Kymab Limited (Cambridge, GB) | 2035-09-09 | RX | Orphan | search |
| Janssen Biotech | STELARA | ustekinumab | INJECTABLE;INJECTION | 761044 | 001 | 2019-11-07 | Start Trial | Kymab Limited (Cambridge, GB) | 2035-09-09 | RX | search | |
| Biogen | ZINBRYTA | daclizumab | INJECTABLE;INJECTION | 761029 | 001 | 2017-05-26 | Start Trial | Kymab Limited (Cambridge, GB) | 2035-09-09 | RX | search | |
| Takeda Pharms Usa | ENTYVIO | vedolizumab | INJECTABLE;INJECTION | 125476 | 001 | 2014-05-20 | Start Trial | Kymab Limited (Cambridge, GB) | 2035-09-09 | RX | search | |
| Genentech | ACTEMRA | tocilizumab | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 125472 | 001 | 2013-10-21 | Start Trial | Kymab Limited (Cambridge, GB) | 2035-09-09 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 9,434,785
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2015132580 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2016139482 | Start Trial |
| United States of America | 10654935 | Start Trial |
| United States of America | 10669342 | Start Trial |
| United States of America | 2016264675 | Start Trial |
| United States of America | 2016368997 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
